CA2008735C - Human epidermal growth factor (egf) receptor sequences and egf competitive monoclonal antibodies - Google Patents

Abstract

Monoclonal antibodies that can substantially inhibit binding of EGF to the EGF receptor, preferred antibody target regions on the receptor, and the use of the antibodies to block tumor cell growth.

Description

SUr~IARY OF THE INVENTION
The control of human cell growth is of medical importance. As a result, growth factors, such as epidermal growth factor (EGF), are of interest, as cell growth is regulated by the interaction between growth factors and their receptors in the cell. Here, we disclose the invention of monoclonal antibodies that are useful because they block the interaction of EGF with human cell receptors and inhibit cell growth. They are also useful because they are analytical reagents of great specificity. Also disclosed are segments of the EGF receptor of value as monoclonal antibody targets and immunogens or immunogen components.
The monoclonal antibodies we discovered are unusual anti-EGF receptor antibodies in that they also recognize deglycosylated and denatured EGF receptors. These properties were essential for us to determine the amino acid sequence of the epitope where the antibodies bind. Taking advantage of these properties and using cyanogen bromide fragments of a truncated form of the EGF receptor secreted by A431 cells (26) and synthetic peptides, we determined that all three antibodies recognize epitopes encompassed by 14 amino acids of the EGF
receptor. This region of the receptor is located between the extracellular cystein-rich domains and includes an Arg-Gly-Asp-Ser recognition sequence for cell adhesion receptors (27).

._ % 2008735 In additional experiments we allowed a truncated from of the human EGF receptor to bind to mouse EGF and then crosslinked the two entities with an amine-reactive crosslinking reagent, disuccinimidyl succinate (DSS). (Mouse EGF, a commonly used substitute for human EGF, was the form of EGF used in all experiments in this application.) This allowed us to pinpoint a single amino acid in the receptor that was linked to the EGF, indicating that the amino acid was in the EGF binding site. Combining the knowledge of the locations of that amino acid with the knowledge of the locations of the three antibody epitopes, as well a;s other information on the structure of the receptor, allowed us to the identify regions of the receptor of particular value as monoclonal antibody targets.
In accordance with an Eambodiment of the present invention there is provided a monoclonal antibody that competes with EGF for binding to the natural EGF receptor and binds to an epitope between residues Ala-351 and Asp-364 of the natural EGF receptor, which epitope remains immunogenically active after denaturation.
In accordance with another embodiment of the present invention there is provided a chemical compound containing an amino acid sequence consisting of al.l or part of the human EGF
receptor segment that extends from residue Phe-321 to residue Glu-367 in natural, denatured or synthetic conformation, said sequence having a length effectivs~ to raise antibodies that compete with EGF binding.
Yet another embodiment of the present invention provides a hybridoma selected from the group consisting of hybridoma ATCC HB 10342, hybridoma A,TCC HB 10343, and hybridoma ATCC HB 10344.
Among the known growth factors and receptors (1), '~200g~'35 intracellular signal transduction initiated by interactions between epidermal growth factor (EGF') and its receptor has been particularly well studied (2-5)" EGF is a 53-residue polypeptide that stimulates the growth of a variety of cell types and is synthesized in the form of an M,. 128,000 precursor molecule. The mature EGF receptor is an M,. 170,000 glycoprotein with intrinsic tyrosine-specific protein kinase activity and contains two functional domains linked by a transmembrane region (11-14). Th;e extracellular domain is heavily glycosylated and possesses a single EGF-binding site, and the intracellular portion of the receptor includes a tyrosine protein kinase domain with three - 2a -COOH-terminal autophosphorylation sites at residues 1068, 1148, and 1173 (14-19). The extracellular domain of the EGF receptor contains a large number of cysteine residues, 51 in total, which are clustered in two regions (14). These cysteine residues are conserved in the extracelluar domain of the chicken EGF receptor which is 75% identical to that of the human receptor (20). Similar clusters of cysteine residues have been found in the extra-cellular portions of the receptors for insulin, insulin-like growth factor I, nerve growth factor, and low density lipoprotein (2). Although these cysteine-rich regions probably contribute to receptor tertiary structure through the formation of intramolecular disulfide bridges, the role of these regions in receptor function has not been elucidated.
Very little is known about the structural features of the EGF receptor that are involved in the binding of EGF.
Carpenter and Cohen observed that several lectins reversibly inhibited the binding of radiolabeled EGF to human fibroblasts (21). However, the antigenic specificities of mono monoclonal antibodies to EGF receptors of A431 human epidermoid carcinoma cells indicate that antibodies which block EGF binding do not recognize carbohydrate determinants while those with carbohydrate specificities do not inhibit EGF binding (22, 23).
These results suggest that N-linked oligosaccharides, which comprise 40% of the mass of the EGF receptor extracelluar domain (2) are not directly involved in EGF binding. In addition, Slieker et al. found that oligosaccharide addition to pro-EGF receptors was necessary to acquire the ability to bind EGF but that deglycosylated receptors retained binding activity (24). Lax et al. have cleaved with cyanogen bromide human EGF receptors cross-linked to l2sl-EGF and have identified with anti-peptide antibodies a labeled Mr 50,000 receptor fragment spanning residues 294-543, which is largely located between the two cysteine-rich regions of the extracellular domain (25). Thus, the EGF-binding site of the receptor resides within a 250-residue region of the extracellular domain. The location of the EGF binding site was not characterized in further detail.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. Effect of monoclonal antibodies on l2sl-EGF
binding to A431 cells. Duplicate cultures of live A431 cells were incubated at 4°C with increasing concentrations of l2sI-EGF
in the absence (filled in circles) or presence of 20 nM LA22 IgG (filled in triang,es) or 20 nM LA58 IgG (filled in squares) as described under "Experimental Procedures". The data are shown in a double reciprocal Lineweaver-Burk plot.
FIG. 2. Immunoreactivity of intact ERRP and deglycosylated ERRP. Full length A431 EGF receptor (1~ 1), ERRP (lanes 2, 4, 6, and 8) and ERRP treated with endoglycosidase F (lanes 3, 5, 7, and 9) were electrophoresed in a 10% polyacrylamide gel under denaturing conditions and electrophoretically transferred to nitrocellulose. The membrane was reacted with monoclonal antibodies LA90 (1-3), LA58 (lanes 4 and 5), 455 IgG (lanes 6 and 7), and LA22 (8 and 9). Bound antibody was detected with l2sl-protein A and autoradiography.

FIG. 3. Reverse phase HPLC chromatography of ERRP
fragments after CNBr cleavage. (A) CNBr-generated ERRP
fragments were fractionated on a C-4 reverse phase column using a 20-60% gradient of acetonitrile in aqueous 0.1% TFA. (B) A
l0 ~1 aliquot of each column fraction was reacted with LA22 in a dot blot assay.
FIG. 4. LA22-reactive Mr 43,000 and Mr 37,000 ERRP
fragments. CNBr fragments in fraction 19 (Fig. 3) were rechromatographed on a C-4 reverse phase HPLC column. The main absorbance peak was analyzed by N-terminal sequencing and electrophoresis. Edman degradation yielded a major amino acid sequence of XEDGV and a minor sequence of XXNPE. Mr 43,000 and Mr 37,000 bands were detected after SDS-PAGE in a 15%
polyacrylamide gel by silver staining (inset, right lane) and western blotting with LA22 antibodies(inset, left lane).
FIG. 5. Schematic representations of the ERRP of A431 cells. The cysteine-rich regions from Cys-133 to Cys-313 and Cys-446 to Cys-612 are hatched. The amino acid sequence deduced from ERRP cDNA (14) for residues 295 through 370, denoted by the ~, is presented below. Consensus sequences for potential asparagine-linked glycosylation sites are overlined, the Arg-Gly-Asp-Ser adhesion molecule recognition site (27) is , and the 14-amino acid peptide recognized by LA22, LA58, and LA90 is . Amino acid differences in the chicken EGF receptor sequence homologous to residues 295 through 370 of the human receptor (20) are indicated.

FIG. 6. LA22-reactive Mr 17,000 ERRP fragment. CNBr fragments in fraction 21 (Fig. 3) were rechromatographed on a C-4 reverse phase HPLC column. Peak C was analyzed by N
terminal sequencing and electrophoresis. Edman degradation yielded an amino acid sequence of EEDGV. The Mr 17,000 ERRP
fragment was detected after SDS-PAGE by silver staining (inset, right lane) and western blotting with LA22 antibodies (inset, left lane) .
FIG. 7. Reverse phase HPLC chromatography of acid-cleaved Mr 43, 000 and Mr 37, 000 CNBr fragments of ERRP. The Mr 43,000 and Mr 37,000 CNBr-generated ERRP fragments (Fig. 4) were cleaved with 0.1% trifluoracetic acid (28) and were chromatographed on a C-4 reverse phase column. Peak D, which reacted with LA22 antibodies in a dot blot assay, was analyzed by N-terminal sequencing and electrophoresis. Edman degradation yielded a major amino acid sequence of EEDGVR and a minor sequence of DVNPEG. This peak was resolved by electrophoresis into bands of Mr 23,000 and Mr 17,000 (inset, left lane) that reacted with L22 antibodies (inset, middle lane). These bands were converted to LA22-reactive bands of lower molecular weight by endoglycosidase F (inset, right lane).
FIG. 8. S. aureus V8 protease digestion of LA22-reactive Mr 43,000 and Mr 37,000 ERRP fragments. The Mr 43,000 and Mr CNBr-generated ERRP fragments (Fig. 4) were digested with S. aureus V8 protease at pH 8.0 (29), and the digestion products were chromatographed in a C-4 reverse phase HPLC
column. Peak E, which reacted with L22 antibodies in a dot blot assay, was analysed by N-terminal sequencing and electrophoresis. Edman degradation yielded a single sequence of FKDSLSIXATNIKHFKXCTSI. By SDS-PAGE, peak I was resolved into a single silver-stained band of Mr 15,000 (inset, right lane) that reacted with LA22 antibodies (inset, left lane).
FIG. 9. Inhibition of antibody binding to ERRP by synthetic peptides. Synthetic peptides of 24 residues (A) and 14 residues (B) corresponding to EGF receptor sequences Asp-344 to Glu-367 and Ala-351 to Asp-364 (Fig. 4) (14), respectively, were used to inhibit the binding of purified LA22 (A, triangles; B, Qnen circles), LA58 (A, circles; B, ~, and LA90 (A; sr~,al res, B, trian~~les) to immobilize ERRP. The inhibition of LA22 binding by purified ERRP (filled in circles) is presented in panel B.
FIG. 10. Immunoprecipitation of the cross-linked fragments produced from [l2sl]EGF-ERRP complexes by Endo-Glu-C.
The reduced and carboxymethylated cross-linking complex was digested by Endo Glu-C and immunoprecipitated by immobilized LA22. The immunoprecipitated fragments was either run on 15%
SDS-PAGE (lane 1) or subjected to further treatment with Endo Glu-C (lane 2) or Endo-F (lane 3) prior to electrophoresis.
The dried gel was exposed to X-ray film.
FIG. 11. Cleavage of [lzsI]EGF-ERRP complexes by Endo Lys-C. Reduced and carboxymethylated cross-linked complexes were subjected to cleavage by Endo Lys-C. The resulting fragments were immunoprecipitated by immobilized LA22, and the immunoprecipitate was either directly run on 15% SDS-PAGE (lane A), or further treated with Endo-F (lane B) or Endo Glu-C (lane C), respectively, before electrophoresis. The dried gel was exposed to X-ray film.
-FIG. 12. Inhibition of A431 growth by EGF receptor monoclonal antibodies. A431 cells were seeded in 24-well plates at 5 x 103 cells/ml in DME/F12 medium, and they were cultured in the presence of increasing concentrations of monoclonal antibodies LA22 (filled in circles) , LA58 (f~
in scruares), and LA90 (filled in triangles) for 6 days at 37°C.
Cells in duplicate wells were harvested by trypsinization and counted with a Coulter particle counter.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The invention is, in its first aspect, a monoclonal antibody that competes with EGF binding to the natural human EGF receptor and binds to an epitope residing on the human EGF
receptor between residues Cys-313 and Cys-446, which epitope remains immunologically active after denaturation. For the purpose of the present specification and claims, "denaturation"
means an alteration of the three-dimensional conformation from that naturally occurring, including deglycosylation and reduction of disulfide bonds, such as, for example, by boiling, treatment with SDS or other strong detergent, and/or treatment with reducing agents, such as ~i-mercaptoethanol. Of course, "denaturation" as used herein does not comprehend conditions so extreme as to cause splitting of the peptide bonds or destruction of the amino acids. Cys-313 and Cys-446 are two residues that mark the limits of two cysteine-rich regions and also encompass the receptor segment that contains both the newly discovered antigenic determinant extending from residue Ala-351 to Asp-364 and the residue which can be cross-linked _ g -to bound EGF, Lys-336: any monoclonal antibody with the foregoing properties is considered part of the invention. In preferred embodiments the invention is either (1) a monoclonal antibody that reacts with an epitope residing on the receptor between residues Cys-113 and Asp-364, (2) one that reacts with an epitope between residues Lys-336 and Asp-364, (3) one that reacts with an epitope residing between residues Ala-351 and Asp-364, (4) one that reacts with the same epitope as a monoclonal antibody produced by a hybridoma selected from the group hybridoma ATCC HB 10342, hybridoma ATCC HB 10343, and hybridoma ATCC HB 10344, or (5) one that is produced by one of those three hybridomas.
In a second aspect, the invention is a chemical compound which includes an amino acid sequence comprising all or part of the human EGF receptor segment that extends from residue Phe-321 to residue Glu-367, said segment being substantially free of the remainder of the receptor. The receptor has a length effective to raise antibodies that compete with EGF binding. Usually, the minimum amino acid length to provide such immur~ogenicity is about ten amino acids.
In preferred embodiments, the chemical compound includes all or part of that portion of the receptor segment that extends from (1) residue Lys-336 to residue Asp-364, or (2) residue Ala-351 to residue Asp-364, in each preferred embodiment said portion or part thereof being substantially free of the remainder of the receptor and other components of human cells.
The segment may be one isolated from human cells by techniques which may or may not cause denaturation of the segment. It may also be one synthesized by known techniques. For those - g -epitopes which bind to antibodies in both the natural or denatured form of the segment bearing the epitopes, a linear synthesized segment will also generate the desired antibodies, regardless of its natural conformation or glycosylation. Of course, the synthetic sequence may comprise segments which contain glycosylated structures or are otherwise manipulated in the laboratory to emulate the natural conformation and structure of the receptor.
The amino acid sequence present in the chemical compound of the present invention is a shortened segment of the entire human EGF receptor and as such does not comprehend the entire native receptor. However, the compound may contain other moieties or sequences for specified purposes, such as, for example, a carrier protein to enhance the immunogenicity of the compound.
Receptor fragments of the present invention may also be produced by recombinant DNA procedures. The DNA encoding the receptor fragment may be synthetic DNA, isolated genomic DNA, cDNA, or a combination thereof. The DNA can then be inserted into any appropriate vector, such as a plasmid or virus, and introduced into an appropriate host cell, either prokaryotic or eukaryotic. Such techniques are set forth, for example, in Sambrook et al, "Molecular Cloning: A Laboratory Manual", Second Edition, Cold Spring Harbor Laboratory Press, 1989. The present invention also comprehends such DNA, vectors and host cells.
In a further aspect, the invention is a process of inhibiting the growth of human cells which are EGF-responsive, which comprises allowing such cells to come into contact with a monoclonal antibody of the present invention.

In another aspect, the invention is the use of compounds including EGF sequences of the present invention in the known procedures of obtaining polyclonal or monoclonal antibodies by subjecting an animal to an immunogen and obtaining the antibodies, or the cells which produce the antibodies, raised in such animals.
The cells may be used to form monoclonal hybridoma cell lines which produce a monoclonal antibody of the present invention.
In yet a further aspect, the present invention is a hybridoma capable of producing a monoclonal antibody in accordance with the present invention, and preferably one of hybridoma ATCC
HB 10342, hybridoma ATCC HB 10343, and hybridoma ATCC HB 10344.
4Aith respect to receptor segments, the segment between residues 321 and 367 is disclosed in this application. The resi-dues from 321 to 336 can be split off with Lys-C endoproteinase.
The linkage between residues 364 anal 365 is acid labile; that property can be used to split off residues 365 to 367. The l4mer between residues 351 and 364 can be: synthesized as described in this application. These methods, i.n combination with other meth-ods described here, allow the production of a segment substantial-ly free of the remainder of the receptor and other components of human cells as indicated by chromatographic and/or electorphoretic analysis.
MATERIALS AND METHODS
Abbreviations: EGF, epidermal growth factor; ERRP, EGF
receptor-related protein; HPLC, high performance liquid chromatog-raphy; SDS, sodium dodecyl sulfate; DME, Dulbecco's Modified - 11 "

~. ~ 2008735 Eagle's medium; BSA bovine serum albumin; ELISA, enzyme-linked immunosorbant assay.
Production of hybridomas and monoclonal antibodies.
Hybridomas were produced by fusing X63-Ag8.653 mouse myeloma cells (30), obtained from the American Type Culture Collection (Rockvile, MD), with splenocytes from Balb/c mice immunized with A431 human epidermoid carcinoma cells (22) as described previously (31,32). The hybridomas were selected in HAT-supplemented RD+5F (factor) medium, (33) containing 5% fetal calf serum (FCS; Hyclone, Logam, UT), and they were subsequently cloned and maintained in RD+5F medium. The monoclonal antibodies LA22, IgG2a, LA58 IgGi, and LA90 IgG2a were selected for their ability t:o inhibit the binding of [l2sl]EGF (receptor grade; Collaborative Research, Bedford, MA) to intact A431 cells (L. Wang and J.D. Sato, unpublished results) as described previously (31,34). Monoclonal antibodies were purified from serum-free hybridoma media by chromatography on protein A-*Ssaphrose (Pharmacia Inc., Piscataway, N.J.) (35). Purified antibodies were dialyzed against phosphate-buffered saline and filter-sterilized.
Monoclonal antibody LA22 l:gG2a, also referred to here as monoclonal antibody LA22, was deposited on January 24, 1990, at the American Type Culture Collection, Rockville, Maryland 20852, and was given the ATCC accession number HB 10342.
Monoclonal antibody LA58 IgGl, also referred to here as monoclonal antibody LA58, was deposited on January 24, 1990, at the American Type Culture Collection, Rockville, Maryland 20852, and was given the ATCC accession number HB 10343.
Monoclonal antibody LA90 IgG2a, also referred to here as monoclonal antibody LA90, was deposited on January 24, 1990, at the American Type Culture Collection, Rockville, Maryland 20852, and was given the ATGC acce:~sion number HB 10344.
*Trade-mark ~

Purification of EGF rece~ator-related protein ~ ERRPI
from conditioned medium. The truncated form of the EGF
receptor (ERRP: 26) secreted by A431 cells was purified from unsupplemented DME/F12 medium (Gibco, Grand Island, NY) conditioned by A431 cells in ro:Ller bottle cultures. The conditioned medium was passed over a column of 528IgG EGF
receptor monoclonal antibody (31, 3~t) immobilized on *Affi-gel (BioRad, Richmond, CA). Bound ERRP was eluted from the column in 0.1 M citrate buffer (pH 4.0), and the elute was 10 dialyzed against distilled water and lyophilized.
Binding assays with EGF and monoclonal antibodies.
The binding assays with EGF and monoclonal antibodies were done with paraformaldehyde-fixed A431 ce7lls in punctured microtiter wells containing glass fiber filters (V and P Enterprises, San Diego, CA). EGF, LA22 IgG, LA58 IgG and LA90 IgG were labeled with Na[lzsl] (Amersham, Arlington Heights, IL) by the chloramine T method. 2x104 A431 cells were incubated in duplicate wells with 0.3 - 0.5 nM l2sl-ligand and increasing concentrations of unlabeled competing ligand in 50 ~1 DME/F12 medium containing 0.2% BSA. After two hours at room temperature the cells were washed *Trade-mark four times with PBS containing 0.25% gelatin and 5% newborn calf serum. Cell-bound radioactivity was measured with a model 1274 LKB gamma counter. Maximum inhibition of binding was measured in the presence of a 200-fold excess of unlabeled homologous ligand.
The competitive nature of the antibody-mediated inhibition of 1251[EGF]-receptor binding was determined with confluent microtiter cultures of live A431 cells. Cells in duplicate cultures were incubated with increasing concentrations of [1251]EGF (2.0x105 cpm/ng) in the presence or absence of 20 nM monoclonal antibody in DME/F12 medium containing 0.5% BSA. After two hours at 4°C the cells were washed three times with 0.5% BSA in DME/F12 medium and were solubilized in 0.1 N NaOH. Cell-bound radioactivity was corrected for non-specific binding in the presence of a 200-fold excess of unlabeled EGF. The results were analyzed in a double-reciprocal Lineweaver-Burk plot.
Zodetection methods with ,purified monoclonal For Western blotting ( 3 6 ) 2 E.cg each of intact A431 EGF receptors, ERRP, ERRP deglycosylated with endoglycosidase F containing peptide N-glycosidase (Boehringer-Mannheim, Indianapolis, IN) or ERRP peptides were electrophoresed in a SDS-polyacrylamide gel (SDS-PAGE) (37) using a miniprotean II apparatus (BioRad). Molecular weight markers were purchased from BioRad. The proteins were electrophoretically transferred with a mini-transblot assembly (BioRad) to 0.45 ~cm or 0.2 ~cm nitrocellulose (Schleicher and Schuell, Kenne, NH) in 25 nM Tris buffer (pH 8.3) containing 192 mM glycine and 20% (v/v) methanol. The nitrocellulose membranes were incubated with a 5% solution of non-fat dry milk for 1 hr and rinsed twice with TBS (20 nM Tris/500 nM NaCl/pIi 7.5) to block non-specific binding sites. The nitrocellulose-bound proteins were incubated overnight at 4°C with purified monoclonal antibodies at 1 fcg/ml in a 1% solution of fraction V BSA (Sigma Chemical Co., St. Louis, MO). The membranes were rinsed with TBS and incubated for 1 hr in a 1:1000 dilution of affinity purified rabbit anti-mouse Ig (Cappel, Malvern, PA) n TBS. After two washes in TBS the nitrocellulose membranes were incubated for 1 hr in a 1:1000 dilution of l2sl-protein A
(50-100 ~CCi/~g; New England Nuclear, Boston, MAO in TBS. TBS-washed and air-dried membranes were exposed to XAR5 film (Kodak, Rochester, NY) and bound antibody was detected by autoradiography. For dot-blotting peptides and protein were adsorbed to 0.2 ~m nitrocellulose membranes (Schleicher and Schuell) in a 96-well dot-blot apparatus (BioRad), and the membranes were reacted with purified monoclonal antibodies and processed as described above.
Selective fragmentation of ERRP and yep purification. Affinity-purified ERRP was reduced with 100 mM
dithiothreitol (Sigma Chemical Co.) and carboxymethylated with iodoacetic acid (Sigma Chemical Co.). Alkylated ERRP was dialyzed against 70% formic acid (Aldrich Chemical Co., Milwaukee, WI) and was cleaved with cyanogen bromide (CNBr:
Aldrick Chem. Co.) in the dark at 20°C for 20 hr. Acid-sensitive aspartyl-prolyl peptide bonds (38,39) were cleaved at 100°C for 30 min at 0.1 % trifluoracetic acid (Pierce Chemical Co., Rockford, IL) as described by '~200873'~
Tarr (28). For cleavage at glut;amic acid residues CNBr-fragments of ERRP were digested with S. aureus V8 protease (Boehringer-Mannheim) at a 10:1 (w/w) ratio in 1% ammonium bicarbonate, pH 8, at 37°C for 24 hr. ERRP was deglycosylated with endoglycosidase F (Boehringer-Mannheim) (6mU/~.cg ERRP) for 12 hr at 37°C in 50 ~.cl 20 mm potassium phosphate (pH 7.0) containing 25 mM EDTA and 0.1% SDS. ERRP peptides were purified by reverse phase HPLC on *Vydac columns (The Separations Group, Hesperia, CA) in aqueous solvents of 0.1%
trifluoracetic acid (Pierce Chemical Co.) and acetonitrile (Burdick and Jackson, Muskeogon, MI) using a Beckman model 344 HPLC gradient system (Beckman Instruments, Inc., San Ramon, CA).
Competitive binding assavs using synthetic ~e_ptides 96-well ELISA plates (Falcon, Oxnard, CA) were incubated overnight at 4°C with 1 ~g/ml purified ERRP in 50 mM ammonium bicarbonate, pH 9.6. Non-specific binding sites were blocked with 5% non-fat dry milk for 1 hr, and the plates were washed twice with 1% fraction V BSA (Sigma chemical Co.) in 20 mM Tris buffer, pH 8.0 (EIA buffer). Purified monoclonal antibodies at 10 nM in EIA buffer were incubated with increasing concentrations of synthetic 24-residue or 14-residue ERRP
peptides (see EXAMPLES) or purified :ERRP for 1 hr at 20°C. The plates were washed three times with EIA buffer, and rabbit and anti-mouse IgG antibodies (1:1000 dilution in EIA buffer;
Cappel) were added. After 1 hr the plates were washed with EIA
buffer and lzsl-protein A (New England Nuclear) in EIA buffer was added for a further hr. After a final *Trade-mark series of washes, the plates were air-dried, and the wells were counted with a model 1274 LKB gamma counter.
Amino acid analysis,. Edman degradation, and yeytide ~vnthesis. Phenylthiocarbamyl amino acid analysis and microsequence analysis were done using a model 420A PTC amino acid analyzer and a model 470 gas phase sequences (both from Applied Biosystems, Inc.), respectively, as described by Crabb et al. (40). All sequences reagents and solvents were from Applied Biosystems. With Beta-lactoglobulin A as a test substrate the sequences gave initial yields of 40% and repetitive yields in excess of 92%. The N-terminal sequences of ERRP fragments were localized by comparison with the primary receptor structure deduced from cloned cDNA (14). Solid phase peptide synthesis was carried out essentially as described by Merrifield (41) using an Applied Biosystems Model 430A
automatic peptide synthesizer. A 24 residue peptide (DLHILPVAFRGDSFTHTPPLDPQD), a 14 residue peptide (AFRGDSFTHTPPLD), and a 4 residue peptide (RGDS) were synthesized using t-butyloxycarbonyl (tBOC-N°lp~"-protected amino acids and "Pam" resins (Applied Biosystems). Side chain protecting groups used were Asp(O Bzl), Ser(Bzl), Thr(Bzl), Arg (NalphaTOS) and His (Bom) where Bzl = benzyl, Tos = toluene sulfoxyl, and Bom = benzyloxymethyl. The remaining amino acids had no side chain protecting groups. All amino acids were obtained from Peninsula Laboratories except tBoc-His(Bom), which was from Bachem. After assembly the protecting groups were removed and the peptide-resin anchoring bond was cleaved with 80-90% (v/v) anhydrous hydrogen fluoride in the presence of anisole and dimethylsulfide. Before use synthetic peptides were purified by reverse phase HPLC and were subjected to amino acid analysis and Edman degradation.
Table I
Amino Acid Analysis Peptide Ea ERRPb Analysis 1 Analysis 2 (Residues 321-367) Asx 6.7 6.5 7 Glx 2.1 2.5 2 Ser 4.3 4.7 5 Gly 2.4 3.2 2 His 3.1 3.4 3 Arg 1.0 1.1 1 Thr 3.9 3.7 4 Ala 2.1 2.3 2 Pro 3.8 3.6 4 Met 0 0 0 Tyr 0 0 0 Val 1.0 1.1 1 Ile 3.8 3.5 4 Leu 4.1 3.8 4 Phe 4.0 3.4 4 Lys 3.2 3.0 3 Total Residues 46 46 46 *Numbers of amino acid residues were calculated assuming a peptide length of 46 residues. Peptide E was generated by V8 protease cleavage of ERRP and was purified by reverse phase HPLC as shown in Fig. 8. 21 and 40 pmol of peptide E were subjected to amino acid analysis.
HComposition inferred from cDNA sequence (14).

i i ~ Iodination of EGF and TGF-alb. Receptor grade EGF (Upstate Biotechnology, Inc. Lake Placid, NY) and synthetic rat TGF-alpha (Peninsula Lab, Belmont, CA) were iodinated with Na[125I]
(Amersham, Arlington Heights, IL) by the chloramine T methid (42) to specific activities of 4.0 x 105 cpm/ng and 3.5 x 105 cpm/ng, respectively.
Cross-linkingv and enzymatic digestion. ERRP was incubated with [ 125I ] EGF or [ 125I ] TGF-alpha at a ratio of 1000 :1 (w/w) for 2 hr at room temperature. Disuccinimidyl suberate (DSS) (Pierce Chemical Co., Rockford, IL) was added to the final concentration of 1 mM. After 20 min, the reaction was stopped by the addition of reduction and alkylation buffer (1 M Tris, pH 8.4, 6 M GnHCl and 5 M EDTA). The detailed procedures for reduction and alkylation were described previously (40). The alkylated cross-linking material was dialyzed in either endoproteinase Glu-C digestion buffer (0.05 M NH4HC0~, pH 7.8) or endoproteinase Lys-C digestion buffer (0.1 M NH,HCO3, pH
9.0). Cleavage by endoproteinase Glu-C (Boehringer-Mannheim, Indianapolis, IN) was carried out at an enzyme-protein ratio of 1:40 (w/w) for 14 hours at room temperature, and cleavage by endoproteinase Lys-C (Boehringer-Mannheim) was performed at a ratio of 1:40 (w/w) for 10 hr at 37°C.
Immunoyrecipitation of ERRP fragments. The protease activity in digests was inactivated by boiling for 2 min and immunoprecipitation was performed by addition of LA22 IgG2 a (43) conjugated to Affi-Gel 10 (BioRad, Richmond, CA) (1 mg antibody/ml gel). After a 1;~ hr incubation at 22°C, the sub>ernatant was removed, and the gel was washed twice with 1% BSA in PBS and twice by PBS or, for further cleavage, by either Endo Gl.u-C digestion buffer or Endo Lys-C digestion buffer. The gels washed with digestion buffers were boiled for 2 min to release pe=ptides from the antibodies.
Proteases were then added to the ge=l slurry and incubated for 10 hrs at room temperature for Endo GI_u-C and at 37°C for Endo Lys-C.
Inhibition or growth of a human tumor cell line A431 cells (22) were plated in 24-well plates (Cost=ar, Cambridge, MA) at 5 x 103 cells/ml in DME/F12 medium. Increasing concentrations of protein A-purified monoclonal antibodies LA22, LA58 and LA90 were added to duplicate wells as indicated in Fic~. 12. After a six day incuba-tion at 37°C, the cells were trypsinized and counted with a Coulter Particle counter (Coulter F'slectronics).
EXAMPLES
Interaction between monoclonal ant_Lbodies and the EGF-binding domain of the EGF receptor Three monoclonal antibod_Les, LA22, LA58, and LA90 were used to study the interaction betwe=en EGF and the ligand-binding domain of the human EGF receptor. All three of the antibodies inhibited the binding of lzsl-EGF i.o A431 human epidermoid carci-noma cells (22) (Table II). In addition, each antibody completely inhibited the binding of the other two antibodies to A431 cells, and the binding of each antibody w<~s inhibited up to 87% by EGF.
''.. .;: _ I
i - 20 _ i ~

Furthermore, the binding of all three antibodies was blocked by the EGF-inhibiting monoclonal antibody 528 IgG (33, 34) but not by the oligosaccharide-specific EGF receptor antibody 455 IgG (32) . Lineweaver-Burk plots of l2sl-EGF binding to live A431 cells in the presence of 20 nM LA22 or 20 nM LA58 indicated that the antibodies did not detectably alter B"~X
(Fig. 1). Similar results were obtained with l2sl-EGF binding to fixed A431 cells in the presence of antibodies at 66 nM
(results not shown). Thus, these antibodies, like 528 IgG (44) mainly inhibited EGF receptor interactions in a competitive manner. These results suggested that the monoclonal antibodies recognized spatially related epitopes and that these antigenic determinants were within, or immediately adjacent to, the receptor EGF-binding site.

i TABLE II
Mutually competitive binding of EGF and monoclonal antibodies Competitive binding assays were done using paraformaldehyde-fixed A431 cells as described under "Experimental Procedures". The concentrations and specific activities of lzSl_labeled ligands were: EGF (0.5 nM, 4.8 x 105 cpm/ng): LA22 (0.3 nM, 1.5 x 105 cpm/ng); LA58 (0.4 nM, 8.0 x 104 cpm/ng) : and LA90 (0.3 nM, 9.3 x 104 cpm/ng) . Competing ligands were added to saturating concentrations. The results are expressed as percent maximum inhibition.
Competing ligand 125I-Ligand ~ Tntorac-tinn of monoclonal antibodies with deylyco~ylated receptor segments Western analysis was used to determine whether the antibodies recognized continuous epitopes as opposed to conformational assembly or carbohydrate determinants on EGF
receptors. The antibodies were reacted within tact or deglycosylated A431 EGF receptor-related protein (ERRP), a truncated form of EGF receptor that is secreted by A431 cells (26). The receptor-related protein is a Mr 105,000 glycoprotein that binds EGF and includes the entire extracellular domain of the EGF receptor ( 14 ) . As shown in Fig. 2, all three monoclonal antibodies bound to both the intact and deglycosylated forms of ERRP. In contrast, 455 IgG
(31), an EGF receptor monoclonal antibody that recognizes a blood group A-related oligosaccharide epitope (45), bound to intact but not to deglycosylated ERRP (Fig. 2, 6 and 7).
These results indicated that LA22, LA90, and LA58 did not recognize endoglycosidase F-sensitive N-linked glycans, and they indicated that the antibodies recognized continuous peptide epitopes.
Fmrt_h_o__r localization of theepitones recogw~i ~.~d by the monoclonal antibodies The ability of the three monoclonal antibodies to react with denatured ERRP was exploited to define the epitopes of these EGF competitive antibodies. Cyanogen bromide (CNBr)-generated fragments of reduced and carboxymethylated ERRP were resolved by reverse-phase HPLC (Fig. 3A), and each fraction was tested for immunoreactivity to LA22 (Fig. 3B). Inspection of the deduced amino acid sequence of ERRP (14) predicted that IgG (32) . Lineweaver-Burk complete cleavage would generate 11 CNBr fragments ranging in size from 9 to 250 amino acids. As shown in Fig. 3, LA22 IgG
reacted most strongly with fractions 19-22 which corresponded to an absorbance peak eluting from the HPLC column between 40-50% acetonitrile. Fraction 19 consisted of a broad peak on reverse-phase HPLC (Fig. 4) which was resolved by SDS-polyacrylamide gel electrophoresis into two immunoreactive bands of Mr 370,000 and 43,000 (Fig. 4, inset). When subjected to amino acid sequencing, this HPLC peak yielded a major sequence (initial yield 38 pmol) staring at Glu-295 (XEDGV ..., Fig. 5) and a minor sequence (initial yield 7 pmol) starting with Asp-254 (XXNPE...) (14). Fraction 21 (Fig. 3) yielded an additional immunoreactive CNBr peptide of Mr 170,000 (C, Fig. 6), which also started with Glu-295 (EEDGV ... , peptide C; initial yield 28 pmol).
The presence of an acid-labile peptide bond between Asp-364 and Pro-365 (14) suggested that Asp-364 was the COOH-terminal amino acid of the Mr 17,000 CNBr peptide. This possibility was supported by the observation that the Mr 43,000 and 37,000 CNBr fragments (Fig. 4) were converted by acid treatment to Mr 23,000 and 17,000 LA22-reactive polypeptides with conserved NH2-terminal amino acid sequences (Fig. 7).
Together these results suggested that the epitope recognized .
by LA22 resided within the 70 amino acids between Glu-295 and Asp-364 (Fig. 5). This 70-residue peptide had two potential N-linked glycosylation sites at Asn-328 and Asn-33? (14). The difference between the apparent molecular weight of this 70-amino acid peptide (Mr 170,000) and that deduced from its primary structure (Mr 9,200) suggested that the peptide was modified at one or both glycosylation sites. Endoglycosidase F digestion of the Mr 23,000 and 17,000 immunoreactive peptides resulted in molecular weight decreases in both peptides (Fig.
7, inset) indicating that these peptides were indeed glycosylated.
To further localize the epitope recognized by LA22, the Mr 43,000 and 37,000 CNBr peptides (Fig. 4, inset) were cleaved with V8 protease at glutamyl residues (29) generating an Mr 15,000 immunoreactive fragment (~ntide E, Fig. 8).
Edman degradation of this peptide yielded a sequence starting with Phe-321 (FKDSLSIXATNIKHFKXCTSI..., initial yield 100 pmol). The first 21 amino acids of this peptide were identical to the corresponding amino acid sequence deduced from cloned EGF receptor cDNA (14) (Fig. 5) with the exception that no detectable PTH yields were obtained for Asn-329 and Asn-337.
These results further suggested that both asparagine residues were glycosylated. Based on the cleavage specificity of V8 protease and the molecular weight of peptide E, the COOH-terminal amino acid of this peptide was predicted to be Glu-367. This prediction was confirmed by amino acid analysis (Table I): the amino acid composition of the Mr 15,000 peptide was virtually identical to the known amino acid composition of the 47-residue sequence from Phe-321 to Glu-367 (14) (Fig. 5).
Analyses of peptides C and E suggested that the epitope for LA22 resided within the 44 amino acids from Phe-321 to Asp-364 (Fig. 5). Preliminary experiments indicated that the reactivity of LA22 for ERRP was abolished by Arg-C
endoproteinase (data not shown). Since erg-353 was the sole arginine residue between Phe-321 and Asp-364 (14) (Fig. 5), it was likely that the epitope for LA22 was within the COOH-terminal portion of this 44-residue amino acid sequence.
Therefore, a 24-residue peptide was synthesized based upon the receptor sequence from Asp-344 to Glu-367, which included the Arg-Gly-Asp-Ser adhesion molecule receptor recognition sequence (27) at residues 353-356. The synthetic 24-mer inhibited the binding of antibodies LA22, LA58, and LA90 to immobilized ERRP
(Fig. 9A): the concentration of the 24-mer needed to inhibit antibody binding by 50% ranged from 0.7 to 2 ,ccM. These results demonstrated that these three mutually competitive antibodies (Table II) recognized closely spaced and perhaps identical antigenic determinants. A synthetic 14-residue peptide, Ala-351 to Asp-364 (Fig. 5), within the 24-mer sequence also effectively inhibited the binding of all three antibodies to ERRP (Fig. 9B) with half-maximal inhibition occurring at concentrations of 1-3 ~.cM. Both synthetic peptides were 10- to 50-fold less effective than intact ERRP in inhibiting antibody binding. Although both peptides included the recognition sequence for adhesion molecule receptors, a synthetic Arg-Gly-Asp-Ser tetramer had no effect on antibody binding to ERRP
(data not shown). From these results the epitopes for the EGF
competitive antibodies LA22, LA58, and LA90 were assigned to a region of the EGF receptor extracellular domain not larger than 14 amino acids, which was flanked by the two cysteine-rich sequences at residues 134-313 and 446-612 (14). The antibody reactive synthetic peptides neither bound lzsl-EGF when immobilized on a plastic substrate nor inhibited l2sl-EGF
binding to A 431 cells (results not shown). Thus, the epitopes for antibodies LA22, LA58, and LA90 did not comprise the entire ligand-binding region of the human EGF receptor.
Discussion of the foregoing' results We have used the truncated Mr 105,000 form of the EGF
receptor secreted by A431 human epidermoid carcinoma cells (26) to define the epitopes of three EGF competitive monoclonal antibodies. The truncated receptor (ERRP) is identical in sequence to the extracellular domain of the full length human EGF receptor, but it includes 17 nonidentical COOH-terminal amino acids starting from residue 617 (14). This form of the EGF receptor is encoded by an overexpressed 2.8-kb mRNA in A431 cells (14).
The monoclonal antibodies under study were raised against intact A431 cells and A431 membrane preparations, and they were selected for the ability to inhibit l2sl-EGF binding to A431 cells. The antibodies LA22, LA58, and LA90 were mutually inhibitory, and they were largely inhibited by EGF in binding to A431 cells (Table II). These three antibodies were therefore, to that extent, similar in their binding properties to the EGF receptor monoclonal antibodies 528, 225, and 579 (31, 34) and distinct from receptor antibody 455 which bound to an oligosaccharide determinant without inhibiting EGF
binding (31,45). The binding of LA22, LA58, and LA90 to A431 cells was completely inhibited by 528 IgG but was not affected by 455 IgG (Table II). Like 528 IgG (44), these antibodies were competitive inhibitors of EGF receptor interactions (Fig.' 1) .

Unlike previously reported EGF competitive monoclonal antibodies (23,31,46), LA22, LA58, and LA90 recognized both denatured and deglycosylated forms of the EGF receptor (Fig.
2). These properties enabled us to analyze the binding of these antibodies to CNB4- and protease-generated ERRP peptides.
Based on the recognition by LA22 of ERRP peptide C, a 70-amino acid fragment, and peptide E, a 47-amino acid V8 protease-generated ERRP peptide, the epitope for LA22 was localized to the 44 amino acids between Phe-321 and Asp-364 (Fig. 5).
Inhibition of the binding of LA22, LA58, and LA90 to ERRP by synthetic peptides (Fig. 9) placed the epitopes for these antibodies within the 14 amino acids from Ala-351 to Asp-364 (Fig. 5). Thus, these three EGF competitive antibodies recognized closely spaced amino acid determinants within a very limited region of the extracellular domain of the EGF receptor.
This region of the receptor is located between the two cysteine-rich regions that span residues 134-313 and residues 446-612 (14).
Although antibodies LA22, LA58, and LA90 bound to a short region of the EGF receptor, it remained possible that they recognize adjacent or overlapping epitopes (47). Studies with synthetic peptide immunogens have indicated that peptides of fewer than 10 amino acids are generally poor immunogens and that the optimum length for immunogenic peptides is 10-15 amino acids (48,49). These findings suggested that the 14-amino acid sequence of the EGF receptor that bound all three antibodies comprised but a single antigenic determinant and that the antibodies had identical antigenic specificities. An Arg-Gly-Asp-Ser recognition site for adhesion molecule receptors ~ occurred with the NH2-terminal half of the antibody-binding 14-mer at receptor residues 353-356 (14). Whether or not this sequence of amino acids can mediate the binding of receptors for fibronectin or other adhesion molecules to EGF receptors is unknown (27). The Arg-Gly-Asp-Ser tetramer was reported to inhibit the attachment of normal rat kidney cells to fibronectin-coated plastic (50), but it did not inhibit the binding of any of the antibodies to immobilized ERRP. Thus, this tetramer does not by itself constitute the epitope recognized by these antibodies. However, we cannot rule out the possibility that it is an integral part of the epitope.
The 14-residue human EGF receptor epitope described here is 71.4% identical to the homologous region of the chicken EGF receptor (Ala-352 to Asp-365) (20). Of the four amino acid differences between the two sequences, two occur in the adhesion receptor recognition tetramer such that the human Arg-Gly-Asp-Ser sequence corresponds to Leu-Gly-Asp-Ala in the chicken receptor (20). The remaining two amino acid differences occur at residues 359 (His to Lys) and 361 (Pro to Leu) of the human receptor (14,20) (Fig. 5). These amino acid alterations may help to explain the 100-fold difference in the of f inities of human and chicken EGF receptors of murine EGF
(20) .
Our results with EGF competitive antibodies are consistent with and extend those of Lax et al (25) who reported that EGF could be covalently cross-linked to the EGF receptor between Met-294 and Asn-544. We have further found, as described below that immobilize LA22 IgG precipitated a Mr a 18,000 V8 protease-generated ERRP fragment cross-linked to l2sl-EGF which suggested that the epitope for the monoclonal antibodies and the receptor residues) covalently linked to EGF
colocalized to the 47 amino acids of ERRP peptide E (Fig. 8) (51). The locations of the cysteine-rich regions in the primary structure of the EGF receptor ( 14 ) suggest that the native conformation of the extracellular domain is of vital importance for the binding of EGF (25) and most EGF competitive antibodies (23). The smallest antibody-reactive synthetic peptide described here does not bind EGF. However, the mutually competitive binding properties of LA22, LA58, LA90, and EGF strongly imply that the 14-amino acid region of the receptor between Ala-351 and Asp-364 participates in the formation of the EGF-binding site. This conclusion supports a model of EGF receptor structure in which a ligand-binding cleft is formed between the two cysteine-rich regions of the extracellular domain.
ERRP secreted by A431 cells contains the entire extracellular domain of the EGF receptor (14). To identify receptor cross-linking sites, [lasl]EGF was covalently cross-linked to ERRP with DSS, and the [l2sl]EGF-ERRP complex was cleaved by proteases. The reduced and alkylated [lzsl]EGF-ERRP
complex was first digested with endoproteinase Glu-C (Endo Glu-C), an enzyme that specifically cleaves at the carboxyl side of glutamyl residues (29). The enzyme was then heat-inactivated and the cleavage products were immunoprecipitated ' with immobilized LA22. Bound peptides were released by boiling in SDS-PAGE sample buffer and were analyzed by electrophoresis and autoradiography. A single radiolabeled Mr 18,000 band was detected (Fig. 10, lane 1). This indicated that the epitope of LA22 was in close proximity to the cross-linked receptor residue(s). To ensure complete cleavage, the Mr 18,000 fragment was treated again with Endo Glu-C. No further shift in mobility or decrease in the intensity of the band was observed (Fig. 10, lane 2).
As noted above, the smallest Endo Glu-C ERRP fragment which contained the LA22 epitope consisted of the 47 amino acids from Phe-321 to Glu-367; this Mr 15,000 peptide included about Mr 9,000 in N-linked carbohydrates distributed between Asn-328 and Asn-337. The Mr 18,000 fragment observed here most likely consisted of this 47 amino acid peptide with a further Mr 3,000 contributed by EGF residues Asn-1 to Glu-24. To confirm this idea, the Mr 18,000 fragment was treated with a mixture of endoglycosidase F and N-glycosidase F (Endo-F).
Endo-F treatment reduced molecular weight of the radiolabeled fragment by about Mr 9,000 (Fig. 10, lane 3). This result was consistent with our previous observation that the Endo Glu-C
fragment was shifted from Mr 15,000 to Mr 6,000 by Endo-F
treatment (43).
According to the amino acid sequence deduced from cloned EGF receptor cDNA (14), this 47 amino acid fragment includes only three lysine residues, Lys-332, Lys-333 and Lys-336, which are potentially available to react with the amine-specific cross-linker DSS. To determine which of these residues were cross-linked to EGF, [l2sl]EGF-ERRP complexes were cleaved with endoproteinase Lys-C (Endo Lys-C), which specifically cleaves peptide bonds on the carboxyl side of lysyl residues (52). At least five LA22-reactive radiolabeled fragments were detected (Fig. 11, lane A), which indicated that the digestion was incomplete. The two smallest Endo Lys-C
fragments immunoprecipitated by immobilized LA22 antibodies were a peptide of approximately Mr 12,500 and a prominent radiolabeled Mr 18,000 peptide. When deglycosylated with Endo F, both bands shifted in molecular weight by approximately Mr 1-2,000 (Fig. 11 lane B). As this shift in molecular weight did not eqixal or exceed Mr 9,000, it was evident that both ERRP
fragments contained only a single glycosylated residue, Asn-337, which was the most proximal to the LA22 epitope (Ala-351 to Asp-364) of the two glycosylation sites between Phe-321 and Glu-367. This experiment further indicated that the oligosaccharides N-linked to Asn-328 and Asn-337 contributed to Mr 7-8,000 and Mr 1-2,000, respectively, to the mass of ERRP.
Since the NH2-termini of the Mr 12, 500 and the Mr 18,000 ERRP fragments resided between Asn-328 and Asn-337, the cleavage specificity of Endo Lys-C indicated that His-334 was the NHZ-terminal residue of both fragments and that Lys-336 was the sole receptor residue that could be cross-linked by DSS to EGF. As EGF possesses no lysyl residues, it is most likely cross-linked to ERRP via the amino group of Asn-1. Although the COOH-terminal residues of the ERRP fragments could not be identified unambiguously, the molecular masses of the [l2sl]EGF-peptide complexes were consistent with the Mr 12,500 fragment terminating with Lys-372 or Lys-375 and the Mr 18,000 fragment ending at Lys-407. The existence of the radiolabeled Mr 18,000 fragment suggested that the cleavage of ERRP by Endo Lys-C at residues 372 and 375 was very inefficient.
To eliminate the possibility that cleavage by Endo Lys-C was occurring at residues other than lysine, the immunoprecipitated fragments generated with Endo Lys-C were digested with Endo Glu-C. Three radiolabeled fragments were expected if Endo Lys-C were acting in a specific manner: an Mr 18,000 band corresponding to receptor fragments from either Phe-321 or Asp-323 to Glu-367, which would result from any fragment bearing the LA22 epitope terminating N-terminal to Lys-333 and C-terminal to Lys-372: and Mr 9,000 receptor fragment corresponding to His-334 to Glu-367, which would be produced from fragments with His-334 as the NH2-tenainal amino acid and any lysyl residue at the COOH-terminus; and a Mr 3,000 peptide representing EGF residues 25 to 53 that would be released by the protease. The Endo Glu-C digest was resolved by SDS-PAGE into three bands of Mr 18,000, Mr 9,500 and Mr 3,000 (Fig. 11, lane C). Thus, the original Endo Lys-C cleavages occurred specifically at lysyl residues even though the reaction did not go to completion.
We applied the same strategy to investigate the EGF
receptor binding site for TGF-alpha. After cross-linking [l2sl]TGF-alpha to ERRP with DSS, the complex was subjected to reduction and alkylation and Endo Glu-C cleavage. An Mr 18,500 band was detected by autoradiography after immunoprecipitation with LA22 antibodies. Complete cleavage was confirmed by the lack of further digestion with ,additional Endo Glu-C. This antibody-reactive Endo Glu-C-generated ERRP fragment was most likely the same as that cross-linked with EGF. That is, the band was composed of the Mr 15,000 forty-seven residue receptor fragment Phe-321 to Gln-367 with a Mr X3,000 TGF-alpha fragment from Val-1 to Gln-26 or Lys-29 to Ala-50. These data indicated that the receptor site cross-linked with TGF-alpha was also in close proximity to the LA22 epitope and was included within the same 47 amino acid ERRP fragment.
r"t,_i_hit~~n of growth of a human tumor cell line The EGF receptor monoclonal antibodies LA22, LA58 and LA90 were tested for the ability to inhibit the growth in vitro of A431 human epidermoid carcinoma cells (22), which contain a large number of EGF receptors. After a 6 day incubation period at 37°C, all three antibodies at concentrations greater than 1 ~Cg/ml severely inhibited A431 proliferation (Fig. 12).
In the presence of 20 ~g/ml of each antibody there was essentially no increase in cell number.
EGF receptor antibodies seem to be most effective against tumor cells that express an abnormally high number of EGF receptors. This situation occurs frequently, but not always, in squamous cell carcinomas, non-neuronal brain tumors, breast cancers, and gastric carcinomas. Such antibodies are not, however, effective against all tumors that express EGF
receptors.
Monoclonal antibodies can be delivered to a patient through either the blood stream or peritoneal cavity and can ' be delivered directly to the tumor site. A preferred embodiment would be chimeric antibodies in which the variable region of the mouse heavy and light chains are spliced through recombinant DNA technology to C regions of human heavy and light chains.

' REFERENCES

1. James, R., and Bradshaw, R.A. (1984) Annu. Rev. Biochem 259-292.

2. Carpenter, G. (1987) Annu. Rev. Biochem, ~, 881-914.

3. Gill, G.N., Bertices, P.J., and Stanton, J.B. (1987) Mol.

Cell. Endocrinol. ~, 169-186.

4. Yarden, Y., and Ullrich, A. (1988) Biochemistry ~, 3113-3119.

5. Schlessinger, J. (1988) Biochemistry ~, 3119-3123.

6. Savage, C.R., Jr., Inagami, T., and Cohen, S. (1972) J.

Biol. Chem. ~,, 7612-7621.

7. Savage, C.R. , Jr. , Hash, J.H. , and Cohen, S. (1973) J.

Biol. Chem. 248, 7669-7672, 8. Carpenter, G., and Cohen, S. (1979) Annu. Rev. Biochem.

g$, 193-216.

9. Gray, A., Dull, T.J., and Ullrich, A. (1983) Nature 303, 722-725.

10. Scott, J., Urdea, M., Quiroga, M., Sanchez-Pescador, R., Fong, N., Selby, M., Rutter, W.J., and Bell, G.I. (1983) Science ~, 236-240.

11. Cohen, S., Carpenter, G., and King, L., Jr. (198) J.

Biol. Chem. 255, 4834-4842.

12. Ushiro, H., and Cohen, S. (1980) J. Biol. Chem 255, 8363-8365.

13. Buhrow, S.A., Cohen, S., and Staros, J.V. (1982) J. Biol.

Chem. 257, 4019-4022.

14. Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tem, A.W., Lee, J., Yarden, Y., Liberman, T.A., Schlessinger, J., Downward, J., Mayes, E.L.V., Whittle, N., Waterfield, M.D., and Seeburg, P.H. (1984) Nature 309, 418-425.

15. Mayes, E., and Waterfield, M.D. (1984) EMBO J. $, 531-537.

16. Childs, R.A., Gregoriou, M., Scudder, P., Thorpe, S.J., Rees, A., and Feizi, T. (1984) EMBO J. $,2227-2233.

17. Cummings, R.D., Soderquist, A.M. and Carpenter, G. (1985) J. Biol. Chem. 260, 11944-11952.

18. Weber, W., Bertices, P.J., and Gill, G.N. (1984) J. Biol.

Chem. 259, 14631-14636 19. Downward, J., Parker, P., and Waterfield, M.D. (1984) Nature $11, 483-485.

20. Lax, I., Johnson, A., Howk, R., Sap, J., Bellot,F., Winkler, M., Ullrich, A., Vennstrom, B., Schlessinger, J., and Givol, D. (1988) Moll Cell Biol. $, 1970-1978.

21. Carpenter, G., and Cohen, S. (1977) Biochem. Biophys.

Res. Commun. ]~, 545-552.

22. Fabricant, R.N., DeLarco, J.E., and Todaro, G. (1977) Proc. Natl. Acad. Sci. U.S.A. fig, 565-569.

23. Sato, J.D., Le, A., and Kawamoto, T. (1987) Methods Enzymol. 146, 63-81.

24. Slieker, L.J., Martensen, T.M., and Lane, M.D. (1986) J.

Biol. Chem. ?~,1, 15233-15241.

25. Lax, I., Burgess, W.H., Bellot, F., Ullrich, A., Schlessinger, J., and Givol, D. (1988) Mol. Cell. Biol.
$, 1831-1834.

26. Weber, W., Gill, G.N., and Spiess, J. (1984) Science 224, 294-297.

27. Rouslahti, E., and Pierschbacher, M.D. (1986) Cell 4.4.

517-518.

28. Tarr, G.E. (1986) Methods of Protein Microcharacterization; A Practical Handbook (Shively, J.E., ed.) pp. 155-194, Humana Press, Clifton, N.J.) 29. Houmard, J. and Drapeau, G.R. (1972) Proc. Natl. Acad.

Sci. x:3506-3509.

30. Kearney, J.F., Radbruch, A., Liesgang, B., and Rajewsky, K. (1979) J. Immunol. 123, 1548-1550.

31. Sato, J.D., Kawamoto, T., Le, A., Mendelsohn, J., Polikoff, J., and Sato, G.H. (1983) Mol. Bio. Med. ~, 511-529.

32. Kawamoto, T., Sato, J.D., Le, A., McClure, D.B., and Sato, G.H. (1983) Anal. Biochem. 130, 445-453 33. Sato, J.D., Kawamoto, T., and Okamoto, T. (1987) J. Exp.

Med. 165, 1761-1766 34. Kawamoto, T., Sato, J.D., Le, A., Polikoff, J., Sato, G.H., and Mendelsohn, J. (1983) Proc. Natl. Acad. Sci.

USA $Q:1337-1341.

35. Ey, P.L., Prowse, S.J., and Jenkin, C.R. (1978).

Immunochem. x:429-436 36. Burnette, W.N. (1981) Anal. Biochem. ~i~:195-203.

r ' 37. Laemli, U.K. (1970) Nature 227:680-685.

38. Janregni=Adell, J., and Marti, J. (1975) Anal. Biochem.

x:468-473.

39. Mole, J.E., Bhown, A.S. and Bennett, J.C. (1977) J.

Immunol. 118: 67-70.

40. Crabb, J.W., Johnson, C.W., Carr, S.A., Armes, L.G., and Saari, J.C. (1988) J. Biol. Chem. 263: 18678-18687.

41. Merrifield, R.B. (1963) J. Am. Chem. Soc. $,~: 2149-2154 42. Hunter, W.M., and Greenwood, F.C. (1962) Nature 194: 495-496.

43. Wu, D., Wang, L., Sato, G.H., West, K.A., Harris, W.R., Crabb, J.W. and Sato, J.D. (1989) J. Biol. Chem. 264:

17469-17575.

44. Gill, G.N., Kawamoto, T., Cochet, C., Le, A., Sato, J.D., Masui, H., McLeod, C., and Mendelsohn, J. (1984) J. Biol.

Chem. 259: 7755-7760.

45. Gooi, H.C., Hounsell, E.F., Lax, I., Kris, R.M., Libermann, T.A., Schlessinger, J., Sato, J.D., Kawamoto, T., Mendelsohn, J., and Feizi, T. (1985) Bioci. Rep. ~:

83-94.

A
46. Murthy U., Basu, A., Rodeck, U., Herlyn, M., Ross, A.H., and Das, M. (1987). Arch Biochem. Biophys. 252:549-560.

47. Benjamin, D.C., Berzofsky, J.A., East, I.J., Gurd, F.R.N:, Hannum, C., Leach, S.J., Margoliash, E., Michael, J.G., Miller, A., Prager, E.M., Reichlin, M., Sercarz, E.E., Smith-Gill, S.J., Todd, P.E., and Wilson, A.C.

(1984) Annu. Rev. Immunol. 2,:67-101.

48. Palfreyman, J.W., Aitchenson, T.C., and Taylor, P. (1984) J. Immunol. Methods $$:149-161.

49. Walter, G. (1986). J. Immunol. Methods $$:149-161.

50. Pierschbacher, M.D. and Ruoslahti, E. (1984) Nature 309:30-33.

51. Wu, D., Wang L., Chi, Y., Sato, G.H., and Sato, J.D.

(1990) Submitted for publication 52. Jekel, P.A., Weijer, and Beinteme, J. (1983) Anal.

Biochem, 134:347-354.

Claims (9)

1. A monoclonal antibody that competes with EGF for binding to the natural EGF receptor and binds to an epitope between residues Ala-351 and Asp-364 of the natural EGF
receptor, which epitope remains immunogenically active after denaturation.

2. A monoclonal antibody in accordance with claim 1, which binds to the same epitope as the monoclonal antibody produced by a hybridoma selected from the group consisting of hybridoma ATCC HB 10342, hybridoma ATCC HB 10343, and hybridoma ATCC HB 10344.

3. A chemical compound consisting of an amino acid sequence corresponding to all or part of the human EGF receptor segment that extends from residue Phe-321 to residue Glu-367 in natural, denatured or synthetic conformation, said sequence having a length effective to raise antibodies that compete with EGF binding.

4. A chemical compound in accordance with claim 10, wherein said sequence consists of all or part of the human EGF
receptor segment that extends from residue Lys-336 to residue Asp-364, in natural, denatured or synthetic conformation, said sequence having a length effective to raise antibodies that complete with EGF binding.

5. A chemical compound in accordance with claim 10, wherein said sequence consists of all or part of the human EGF
receptor segment that extends from residue Ala-351 to residue Asp-364, in natural, denatured or synthetic conformation, said sequence having a length effective to raise antibodies that compete with EGF binding.

6. Use of a monoclonal antibody in accordance with claim 1 for inhibiting the growth of human cells which are EGF-responsive.

7. The process of raising antibodies by subjecting an animal to an immunogen and obtaining the antibodies, or the cells which produce the antibodies, raised in response to said immunogen, the improvement wherein said antibodies compete with EGF binding and wherein said immunogen is a chemical compound in accordance with claim 3.

8. A hybridoma capable of producing a monoclonal antibody in accordance with claim 1.

9. A hybridoma selected from the group consisting of hybridoma ATCC Hb 10342, hybridoma ATCC HB 10343, and hybridoma ATCC HB 10344.